ProShare Advisors’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,809
| Closed | -$274K | – | 1922 |
|
|
2026
Q1 | $274K | Buy |
+6,809
| New | +$147K | ﹤0.01% | 1387 |
|
|
2024
Q4 | – | Sell |
-7,197
| Closed | -$208K | – | 2273 |
|
|
2024
Q3 | $208K | Sell |
7,197
-295
| -4% | -$10.9K | ﹤0.01% | 1707 |
|
|
2024
Q2 | $287K | Sell |
7,492
-960
| -11% | -$43.5K | ﹤0.01% | 1317 |
|
|
2024
Q1 | $497K | Buy |
8,452
+881
| +12% | +$56.2K | ﹤0.01% | 1085 |
|
|
2023
Q4 | $453K | Sell |
7,571
-121
| -2% | -$6.14K | ﹤0.01% | 1095 |
|
|
2023
Q3 | $293K | Buy |
7,692
+157
| +2% | +$6.9K | ﹤0.01% | 1219 |
|
|
2023
Q2 | $686K | Sell |
7,535
-11,439
| -60% | -$987K | ﹤0.01% | 825 |
|
|
2023
Q1 | $1.25M | Sell |
18,974
-3,663
| -16% | -$211K | ﹤0.01% | 701 |
|
|
2022
Q4 | $1.17M | Buy |
22,637
+1,569
| +7% | +$83.2K | ﹤0.01% | 710 |
|
|
2022
Q3 | $1.44M | Buy |
21,068
+2,558
| +14% | +$151K | 0.01% | 670 |
|
|
2022
Q2 | $836K | Sell |
18,510
-5,235
| -22% | -$239K | ﹤0.01% | 793 |
|
|
2022
Q1 | $1.21M | Sell |
23,745
-5,406
| -19% | -$239K | ﹤0.01% | 849 |
|
|
2021
Q4 | $1.38M | Buy |
29,151
+2,257
| +8% | +$88.9K | ﹤0.01% | 883 |
|
|
2021
Q3 | $886K | Sell |
26,894
-4,419
| -14% | -$248K | ﹤0.01% | 945 |
|
|
2021
Q2 | $1.98M | Buy |
31,313
+4,134
| +15% | +$213K | 0.01% | 726 |
|
|
2021
Q1 | $1.17M | Buy |
27,179
+2,186
| +9% | +$103K | ﹤0.01% | 907 |
|
|
2020
Q4 | $1.43M | Buy |
24,993
+5,446
| +28% | +$230K | 0.01% | 739 |
|
|
2020
Q3 | $590K | Sell |
19,547
-680
| -3% | -$20.3K | ﹤0.01% | 884 |
|
|
2020
Q2 | $661K | Buy |
20,227
+6,571
| +48% | +$211K | ﹤0.01% | 831 |
|
|
2020
Q1 | $366K | Sell |
13,656
-6,780
| -33% | -$241K | ﹤0.01% | 816 |
|
|
2019
Q4 | $626K | Sell |
20,436
-2,313
| -10% | -$64K | ﹤0.01% | 967 |
|
|
2019
Q3 | $548K | Buy |
22,749
+471
| +2% | +$13K | ﹤0.01% | 952 |
|
|
2019
Q2 | $565K | Sell |
22,278
-717
| -3% | -$14.6K | ﹤0.01% | 965 |
|
|
2019
Q1 | $448K | Buy |
22,995
+127
| +0.6% | +$2K | ﹤0.01% | 1057 |
|
|
2018
Q4 | $302K | Buy |
+22,868
| New | +$351K | ﹤0.01% | 1147 |
|
Other funds holding APLS
ProShare Advisors's APLS Position: Q2 2026 in Review
ProShare Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,809 shares — an estimated $274K sold.
ProShare Advisors first reported a position in APLS in Q4 2018 and held it in 25 quarters. The position peaked at $1.98M in Q2 2021. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- ProShare Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- ProShare Advisors sold 6,809 Apellis Pharmaceuticals shares in Q2 2026, an estimated $274K.
- ProShare Advisors first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 25 quarters.
- ProShare Advisors's Apellis Pharmaceuticals position peaked at $1.98M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.